Cynthia Schwalm

Cynthia Schwalm (board member) discloses dealings in 3 companies, chiefly Lisata Therapeutics, Inc., G1 Therapeutics, Inc. and Kadmon Holdings, Inc. In total, 7 filings cover trades dated from 26 December 2018 to 17 June 2021.

Purchases make up the whole of the open-market record (3 purchases, €112k). Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 4 share grants.

A typical purchase (the median) is worth €27k. 3 out of 3 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The latest filing, published on 21 June 2021, reports a share grant in G1 Therapeutics, Inc. The most recent open-market purchase was published on 12 March 2020, 2,416 days ago. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.